Overcoming intrinsic and acquired cetuximab resistance: an in vitro study on the potential of afatinib in HNSCC cell lines

被引：0
|
作者：
De Pauw, Ines
Wouters, An
Van den Bossche, Jolien
Deschoolmeester, Vanessa
Pauwels, Patrick
Vermorken, Jan B.
Peeters, Marc
Lardon, Filip
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4102
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib
    Janjigian, Y. Y.
    Groen, H. J.
    Horn, L.
    Smit, E. F.
    Fu, Y.
    Wang, F.
    Shahidi, M.
    Denis, L. J.
    Pao, W.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E)
    Horn, L.
    Gettinger, S.
    Camidge, R.
    Smit, E.
    Janjigian, Y.
    Pao, W.
    Schnell, D.
    Wang, B.
    Chand, V.
    Groen, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S39 - S40
  • [23] Overcoming Intrinsic and Acquired Resistance Mechanisms Associated with the Cell Wall of Gram-Negative Bacteria
    Impey, Rachael E.
    Hawkins, Daniel A.
    Sutton, J. Mark
    Soares da Costa, Tatiana P.
    ANTIBIOTICS-BASEL, 2020, 9 (09): : 1 - 19
  • [24] CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
    Niehr, Franziska
    Weichert, Wilko
    Stenzinger, Albrecht
    Budach, Volker
    Tinhofer, Ingeborg
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [25] CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
    Franziska Niehr
    Wilko Weichert
    Albrecht Stenzinger
    Volker Budach
    Ingeborg Tinhofer
    Journal of Translational Medicine, 13
  • [26] Mechanisms underlying resistance to cetuximab in the HNSCC cell line: Role of AKT inhibition in bypassing this resistance
    Rebucci, Magali
    Peixoto, Paul
    Dewitte, Amelie
    Wattez, Nicole
    De Nuncques, Marie-Adeline
    Rezvoy, Nicolas
    Vautravers-Dewas, Claire
    Buisine, Marie-Pierre
    Guerin, Eric
    Peyrat, Jean-Phlippe
    Lartigau, Eric
    Lansiaux, Amelie
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (01) : 189 - 200
  • [27] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
  • [28] Overcoming the Acquired Resistance to Afatinib (BIBW2992) in HCC827, a Non-small Cell Lung Cancer Cell Line
    Hsu, J.
    Lin, W.
    Lien, T.
    Yen, K.
    Chang, W.
    Jiang, S.
    Chao, Y.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S129 - S129
  • [29] PHARMACOLOGICAL AND MOLECULAR CHARACTERIZATION OF INTRINSIC AND ACQUIRED DOXORUBICIN RESISTANCE IN MURINE TUMOR-CELL LINES
    SCHOTT, B
    LONDOSGAGLIARDI, D
    RIES, C
    HUET, S
    ROBERT, J
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1993, 119 (09) : 527 - 532
  • [30] IN-VITRO PLATINUM DRUG CHEMOSENSITIVITY OF HUMAN CERVICAL SQUAMOUS-CELL CARCINOMA CELL-LINES WITH INTRINSIC AND ACQUIRED-RESISTANCE TO CISPLATIN
    MELLISH, KJ
    KELLAND, LR
    HARRAP, KR
    BRITISH JOURNAL OF CANCER, 1993, 68 (02) : 240 - 250
12345